Genentech's polatuzumab vedotin meets in Phase II for DLBCL

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional data from the Phase II portion of the Phase Ib/II GO29365 trial in 80 patients with relapsed or refractory

Read the full 295 word article

User Sign In